French doctor and businessman
.mw-parser-output .hidden-begin{box-sizing:border-box;width:100%;padding:5px;border:none;font-size:95%}.mw-parser-output .hidden-title{font-weight:bold;line-height:1.6;text-align:left}.mw-parser-output .hidden-content{text-align:left}@media all and (max-width:500px){.mw-parser-output .hidden-begin{width:auto!important;clear:none!important;float:none!important))You can help expand this article with text translated from
the corresponding article in French. (May 2020) Click [show] for important translation instructions.
Machine translation, like
DeepL or
Google Translate, is a useful starting point for translations, but translators must revise errors as necessary and confirm that the translation is accurate, rather than simply copy-pasting machine-translated text into the English Wikipedia.
Consider
adding a topic to this template: there are already 6,219 articles in the
main category, and specifying|topic= will aid in categorization.
Do not translate text that appears unreliable or low-quality. If possible, verify the text with references provided in the foreign-language article.
You must provide
copyright attribution in the
edit summary accompanying your translation by providing an
interlanguage link to the source of your translation. A model attribution edit summary is Content in this edit is translated from the existing French Wikipedia article at [[:fr:Jacques Servier]]; see its history for attribution.
You may also add the template ((Translated|fr|Jacques Servier)) to the
talk page.
For more guidance, see
Wikipedia:Translation.
Jacques Servier |
---|
Born | (1922-02-09)9 February 1922
|
---|
Died | 16 April 2014(2014-04-16) (aged 92)
|
---|
Nationality | French |
---|
Occupation(s) | Businessman Founder of Laboratoires Servier |
---|
Jacques Servier (9 February 1922 – 16 April 2014) was a French doctor and businessman. He was the founder and president of Laboratoires Servier, a pharmaceutical company.[1]
Biography
Founder of the pharmaceutical group Servier in 1954, he had a fortune estimated at US$7.7 billion.[2]
The group led by him, Servier, had been convicted several times to pay damages for Mediator, trade name of benfluorex. There was a class action also for Isoméride, trade name of dexfenfluramine. There are also active discussions and trial around benfluorex.[3][4]